Gilead, Arcus’ PhII gastroesophageal cancer data argue for TIGIT antibody drug class potential

Gilead and partner Arcus Biosciences’ anti-TIGIT-based regimen has shown early signs of efficacy in a small group of gastroesophageal cancer patients in a mid-stage trial, marking a potential uplift for the TIGIT field after a track record of setbacks.

The Phase II EDGE-Gastric trial is evaluating…
Click here to view original post